Breast Cancer
Conditions
Keywords
Advanced, Metastatic, Breast cancer
Brief summary
The purpose of this study is to assess the effectiveness and safety profile of Aiyi®(Tegafur Gimeracil Oteracil Potassium Capsule, TS-1) as a second line therapy in Chinese female patients with advanced metastatic breast cancer.
Detailed description
Tegafur Gimeracil Oteracil Potassium Capsule is a novel oral derivative of the 5-fluorouracil(5-FU) prodrug tegafur combined with two modulators. Recent clinical trial has reported the promising effect of Tegafur Gimeracil Oteracil Potassium Capsule in metastatic breast cancer. The innovative drug, S-1, has obtained the approval of treatment of advanced breast cancer in Japan, meanwhile, Generic drug is only approved for the indication of gastric cancer in China mainland by Chinese authority, SFDA, and no Chinese clinical study data of TS-1 in breast cancer so far.
Interventions
Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg\*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,
Sponsors
Peking University Cancer Hospital & Institute
Beijing Chao Yang Hospital
Chinese PLA General Hospital
China-Japan Friendship Hospital
Tianjin Medical University Cancer Institute and Hospital
Hebei Tumor Hospital
Chinese Academy of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age: 18-75 years old female. * ECOG status: 0-2. * Life expectancy of ≥ 3 months. * Histologic or cytologic diagnosis of breast cancer. * Progression after receiving one standard prior chemotherapy regimen for recurrent or metastatic lesion except an endocrine regimen. * At least one measurable lesion of \>=2 cm (\>=1 cm on spiral CT scan)according to RECIST (v1.1). * Adequate organ functions: * Hematopoietic: Hemoglobin ≥90g/L, Absolute neutrophil count ≥1.5×10\^9/L, Platelet count ≥80×10\^9/L. * Biochemistry: TBil ≤1.5 times upper limit of normal (ULN), AST and ALT ≤2.5× ULN(≤5x ULN if due to liver metastases), Creatinine ≤1.0×ULN and Creatinine clearance \>50 ml/min. * Women with children potential must have negative pregnancy tests 7 days prior to enrollment and be willing to practice acceptable methods of birth control during the study and 8 weeks after last drug administered. * Ability to take oral medication . * Signed informed consent.
Exclusion criteria
* Pregnancy or lactation or no effective contraception in fertile patients. * Prior treatment with 5-FU or drugs of same class(excluding patients that relapsed more than one year after adjuvant therapy). * Less than 4 weeks since prior investigational agents. * conditions impacting oral drug taking or absorption (e.g. inability to swallow, gastrointestinal resection, chronic diarrhea, intestinal obstruction). * Organ invasion with rapid progression(e.g. lesions exceeding half of Liver or Lung). * CNS or psychiatric disorders. * Allergic to 5-FU. * Only with bone metastases and no measurable lesions. * Clinically significant heart diseases (e.g.congestive heart failure, ventricular arrhythmia, myocardial infarction) before enrollment. * Serious peptic ulcer disease or digestive disorders. * Bone marrow (Hemoglobin \<90g/dl, ANC \<1.5×10\^9/L, Platelet count \<75×10\^9/L). * Renal function disorder (Creatinine \>1.0×ULN). * Liver function disorder (TBil \>1.5×ULN). * Uncontrolled brain metastases. * Noncompliance with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | Up to 2 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical response rate | Every six weeks | Assessed by RECIST v1.1 criteria. |
| Adverse events | Subjects will be followed from date of enrollment until the date of last visit, anticipated up to 2 years | — |
Countries
China
Contacts
Primary ContactPeng Yuan, MD
Outcome results
None listed